|(2Z,5Z)-5-(3-氯-4-((R)-2,3-二羟基丙氧基)亚苄基)-2-(丙亚胺基)-3-(邻甲苯基)噻唑烷-4-酮|CsnPharm

CAS No.: 854107-55-4

Ponesimod Catalog No. CSN12827

Synonyms: ACT-128800

Ponesimod is a selective S1P1 receptor modulator with EC50 of 5.7 nM, used in the reserch of treatment of multiple sclerosis (MS) and psoriasis.

规格	价格	促销价格	库存	数量

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

加入购物车大规格询价

加入收藏

产品咨询

400-920-2911

sales@csnpharm.cn

tech@csnpharm.cn

纯度 & 质量文件批次:

靶点选择性

生物活性

实验方案

技术信息

生物活性

描述S1P is a signaling lipid that regulates many cellular processes in mammals^[3]. Ponesimod is a potent, selective, and orally active S1P(1) receptor agonist (IC50=6nM) selected for clinical development^[4]. Ponesimod activated S1P(1)-mediated signal transduction with high potency (EC50-5.7nM) and selectively. Oral administration of ponesimod (3-100mg/kg) to rats led to a dose-dependent decrease of blood lymphocyte count. Ponesimod (30 mg/kg) also prevents footpad swelling in a rat model of adjuvant-induced arthritis^[5].
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01208090	Psoriasis	Phase 2	Completed	-	-
NCT01006265	Multiple Sclerosis	Phase 2	Completed	-	-
NCT02223832	Healthy	Phase 1	Completed	-	United States, Hawaii ... more >> Hawaii Clinical Research Center Honolulu, Hawaii, United States, 96813 Collapse <<

更多
参考文献

实验方案

计算器摩尔计算器总药量计算器工作液计算器
储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.1693 mL
- 10.8466 mL
- 21.6932 mL
- 5 mM
- 0.4339 mL
- 2.1693 mL
- 4.3386 mL
- 10 mM
- 0.2169 mL
- 1.0847 mL
- 2.1693 mL

技术信息

CAS号

854107-55-4

储存条件

粉末: Sealed in dry,2-8°C

液体: -20°C:3-6 月 -80°C:12月

分子式

C23H25ClN2O4S

运输

蓝冰

分子量

460.97

别名

ACT-128800

溶解度

DMSO	205.0 mg/mL (444.7 mM)
Water	insoluble

动物实验配方

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01208090	Psoriasis	Phase 2	Completed	-	-
NCT01006265	Multiple Sclerosis	Phase 2	Completed	-	-
NCT02223832	Healthy	Phase 1	Completed	-	United States, Hawaii ... more >> Hawaii Clinical Research Center Honolulu, Hawaii, United States, 96813 Collapse <<
NCT02068235	Healthy	Phase 1	Completed	-	United Kingdom ... more >> Simbec Research Limited Merthyr Tydfil, United Kingdom, CF48 4DR Collapse <<
NCT02126956	Pharmacokinetics	Phase 1	Completed	-	Switzerland ... more >> Swiss Pharma Contract Allschwil, Switzerland Collapse <<
NCT02029482	Safety and Tolerability	Phase 1	Completed	-	United Kingdom ... more >> Quintiles Drug Research Unit at Guyʼs Hospital London, United Kingdom, SE1 1YR Collapse <<
NCT02907177	Multiple Sclerosis	Phase 3	Recruiting	March 31, 2020	-
NCT01093326	Multiple Sclerosis	Phase 2	Active, not recruiting	December 15, 2021	-
NCT02425644	Multiple Sclerosis	Phase 3	Active, not recruiting	May 15, 2019	-
NCT03232073	Multiple Sclerosis	Phase 3	Enrolling by invitation	April 2, 2022	-
NCT00852670	Plaque Psoriasis	Phase 2	Completed	-	Austria ... more >> Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie Graz, Austria, 8036 University Klinik of Vienna Vienna, Austria, 1090 France Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud Lyon, France, 69000 CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie Nice, France, 6202 Dermatologie, Hôpital Purpan Universtité Paul Sabatier Toulouse, France, 31000 Germany Klinik für Dermatologie Venerologie und Allergologie Berlin, Germany, 10117 Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany, 20246 Department of Dermatology University Hospital Johannes Gutenberg-University Mainz Mainz, Germany, 55131 University Clinic Münster Clinic and Policlinic for skin diseases Muenster, Germany, 48149 Hungary Semmelweis Universtity Dept. dermato-venerology and skin oncology Budapest, Hungary, 1085 UNIVERSITY OF DEBRECEN Department of dermatology Debrecen, Hungary, 4012 University of Szeged Department of dermatology and allergology Szeged, Hungary, 6720 Veszprem County Csolnoky Ferenc Hospital Dermatology Department Veszprem, Hungary, 8200 Serbia Clinical Centre of Nis Clinic of Dermato-venerology Nis, Serbia, 18000 Collapse <<
NCT02136888	Healthy	Phase 1	Completed	-	United States, Indiana ... more >> Covance Clinical Research Unit (CRU) Evansville, Indiana, United States, 47710 Collapse <<
NCT02461134	Chronic Graft Versus Host Dise... more >>ase Collapse <<	Phase 2	Terminated(Low recruitment)	-	United States, Arizona ... more >> Virginia Piper Cancer Institute Scottsdale, Arizona, United States, 85258 United States, California Moore Cancer Center - UCSD La Jolla, California, United States, 92093 David Geffen School of Med at UCLA Los Angeles, California, United States, 90095 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Indiana Indiana University Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892-1203 United States, Minnesota University of Minnesota - Masonic Cancer CTR CLIN TRIALS CTR Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington Univ School of Med, Oncology (St.Louis) Saint Louis, Missouri, United States, 63110 United States, New York Stony Brook Univ. Medical Center Stony Brook, New York, United States, 11794 United States, Washington Fred Hutchinson Cancer Res CTR Seattle, Washington, United States, 98109-1023 Collapse <<
NCT02461134	-	-	Terminated(Low recruitment)	-	-

Ponesimod Catalog No. CSN12827

靶点选择性

请登录您的专属账户

确认信息